trending Market Intelligence /marketintelligence/en/news-insights/trending/X7Do18B95_GC8wR8bTwTXg2 content esgSubNav
In This List

Cochlear gets US FDA approval for Osia 2 ear implant

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cochlear gets US FDA approval for Osia 2 ear implant

Australia's Cochlear Ltd. said the U.S. Food and Drug Administration approved its Osia 2 System, an implantable hearing solution that uses wireless technology.

The healthcare equipment company expects to make the device commercially available for patients in the U.S. in early 2020.

The FDA also approved Cochlear's Nucleus Profile Plus series ear implant in June. The agency classifies cochlear implants as Class III devices, which go through the highest level of regulatory scrutiny.